A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a phase II clinical trial in treated patients with advanced solid tumors with
FGF/FGFR gene alterations. The purpose of this study is to evaluate the efficacy and safety
of ICP-192.